However, there is now clinical evidence to support their use in other molecular subsets of cancers beyond HR-deficient BRCA1/2-mutant cancers (52,53) or in combination with other targeted drugs to potentiate the clinical efficacy of modern cancer therapies (54–56). The gene discussed is BRCA1; the disease is cancer.